Restart Life Sciences (XCNQ:HEAL) FCF Margin % : 0.00% (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Restart Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Restart Life Sciences's Free Cash Flow for the three months ended in Mar. 2025 was C$-0.24 Mil. Restart Life Sciences's Revenue for the three months ended in Mar. 2025 was C$0.00 Mil. Therefore, Restart Life Sciences's FCF Margin % for the quarter that ended in Mar. 2025 was 0.00%.

As of today, Restart Life Sciences's current FCF Yield % is -7.82%.

The historical rank and industry rank for Restart Life Sciences's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Restart Life Sciences was -7790.91%. The lowest was -12557.14%. And the median was -10174.03%.

XCNQ:HEAL's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -102.175
* Ranked among companies with meaningful FCF Margin % only.

Restart Life Sciences FCF Margin % Historical Data

The historical data trend for Restart Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences FCF Margin % Chart

Restart Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-7,790.91

Restart Life Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Restart Life Sciences's FCF Margin %

For the Biotechnology subindustry, Restart Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Restart Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Restart Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Restart Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-0.072	/	0
	=	%

Restart Life Sciences's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-0.235	/	0
	=	%

Restart Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Restart Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (XCNQ:HEAL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NMLSF:USA HN30:Germany

Address

700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.restartlife.co

Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. Its focus is on creating health foods that address the needs of this community. Its flagship developments include natural remedies for individuals on the Autism Spectrum, Specialty Health Foods, Psilocybin Clinical Trial for Fragile X Syndrome, and Orphan Drug Designation (FDA and EMA). The company operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada.

Executives

Derek Lloyd Harry Ivany	10% Security Holder, Director, Senior Officer
Steven Feldman	Director
William Rascan	Director, Senior Officer